Ralf Wagner

Ralf Wagner joined 2bind in 2017 as a Scientific Advisor.

Since June 2014, Ralf is chairing the Lophius supervisory board to coordinate strategic activities and support the companies further development.

Prior to that, he served almost 13 years as CEO of GENEART AG, a German biotech company, which he founded in 1999 as spin-off of his research group at the University of Regensburg. Under his leadership, GENEART went public in 2006 at the Frankfurt stock exchange and was acquired by Life Technologies in 2010. As CEO and VP Synthetic Biology, he also coordinated the integration activities of the Regensburg based GENEART into the US Company.

Ralf is also Professor for Medical Microbiology and Gene Therapy and member of the Medical Faculty of the University of Regensburg. Beside his management and scientific skills, he brings an excellent professional network of partners in academic research, pharma and biotech industry as well as financing.